Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Flavonoid found in citrus slows lung cancer cell growth in lab tests (opens in a new tab)

medicalxpress.com · 2026-10-20

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 5 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. Two of eight check out. Five claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8OverstatedIn lab experiments, quercetin slowed the division of lung cancer cells and almost completely stopped their migration.View evidenceHide evidence

As statedalmost completely

Why this verdict

The abstract supports reduced proliferation/cell-cycle effects and suppressed migration in A549 and H520 lung cancer cell lines. However, the headline-level wording that migration was 'almost completely stopped' adds a strong magnitude that is not provided in the abstract profile, which reports no quantitative effect size or extent of migration inhibition. The headline therefore outruns what the abstract-level evidence can support.

1

Study evidence

Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.

“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
Claim 2 of 8Not coveredQuercetin is found in citrus fruits, onions and buckwheat and is known for its anti-inflammatory properties.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that quercetin is framed as having anti-tumoral/anti-inflammatory effects, but it does not verify the specific food-source list of citrus fruits, onions, and buckwheat. At abstract depth, this composite lead claim is only partly checkable.

1

Study evidence

In an ex vivo model, quercetin treatment resulted in induction of interferon alpha-2 (IFN-α2), described by the authors as an anti-tumor cytokine.

“In the ex vivo model, quercetin treatment resulted in the induction of interferon alpha-2 (IFN-α2), a well-known anti-tumor cytokine.”
Claim 3 of 8Not coveredThe researchers examined quercetin in lung cancer cells in the lab, on mouse lung sections, and in living mice.View evidenceHide evidence

Why this verdict

The profile supports that quercetin was examined in human lung cancer cell lines, an in vivo murine model, and an ex vivo model. But the abstract-level profile does not specify that the ex vivo material consisted of mouse lung sections, so that specific experimental description is not verifiable at this evidence depth.

1

Study evidence

Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.

“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
2

Study evidence

Quercetin decreased tumor load in an in vivo murine lung cancer model without affecting body weight (reported in the abstract).

“In an in vivo model, quercetin decreased the tumor load without affecting the body weight.”
Claim 4 of 8Not coveredIn one of the two lung cancer cell types studied, quercetin reduced oxidative stress.View evidenceHide evidence

Why this verdict

The abstract supports that quercetin reduced oxidative stress in treated tumor cells, but it does not specify that this occurred in only one of the two lung cancer cell types studied. That cell-line-specific qualification may be true in the full paper, but it is not verifiable from the abstract-level profile.

1

Study evidence

Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.

“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
Claim 5 of 8Not coveredQuercetin decreased EGFR and PD-L1 in the studied cancer cells and increased interferon-alpha-2 in mouse lung sections.View evidenceHide evidence

Why this verdict

The profile supports decreased EGFR and PD-L1 expression, explicitly described for A549 cells in vitro, and supports IFN-α2 induction in an ex vivo model. However, the abstract-level profile does not verify that IFN-α2 was increased specifically in mouse lung sections, and it does not clearly establish EGFR/PD-L1 decreases across all studied cancer cells. The core directions are consistent, but the story’s experimental specificity is not verifiable at abstract depth.

1

Study evidence

Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.

“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
2

Study evidence

In an ex vivo model, quercetin treatment resulted in induction of interferon alpha-2 (IFN-α2), described by the authors as an anti-tumor cytokine.

“In the ex vivo model, quercetin treatment resulted in the induction of interferon alpha-2 (IFN-α2), a well-known anti-tumor cytokine.”
Claim 6 of 8Not coveredThe authors suggest a quercetin-rich diet could support lung cancer treatment and may have preventive effects, but they say more research is needed.View evidenceHide evidence

Why this verdict

The abstract-level profile supports preclinical anti-tumor and immunomodulatory findings for quercetin, but it does not verify the quoted author suggestion that a quercetin-rich diet could support lung cancer treatment or have preventive effects. Diet-based treatment support and prevention are translational claims beyond what is stated in the supplied abstract profile.

1

Study evidence

Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.

“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
2

Study evidence

Quercetin decreased tumor load in an in vivo murine lung cancer model without affecting body weight (reported in the abstract).

“In an in vivo model, quercetin decreased the tumor load without affecting the body weight.”
Claim 7 of 8SupportedResearchers at Universitätsklinikum Erlangen at FAU investigated how quercetin could help treat lung cancer.View evidenceHide evidence

Why this verdict

The paper profile states that the authors evaluated quercetin’s therapeutic potential and anti-cancer properties in lung cancer using in vitro, in vivo, and ex vivo models. This supports the story’s framing that researchers investigated how quercetin could help treat lung cancer, provided it is understood as preclinical therapeutic-potential research rather than evidence of clinical efficacy in humans.

1

Study evidence

Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.

“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
2

Study evidence

Quercetin decreased tumor load in an in vivo murine lung cancer model without affecting body weight (reported in the abstract).

“In an in vivo model, quercetin decreased the tumor load without affecting the body weight.”
Claim 8 of 8SupportedIn the mouse model, the researchers found indications of fewer tumor foci with quercetin, but further studies are needed and transfer to humans is unclear.View evidenceHide evidence

As statedfewer

Why this verdict

The abstract reports that quercetin decreased tumor load in an in vivo murine lung cancer model, which is consistent with the story’s hedged description of fewer tumor foci. The story also appropriately notes that further studies are needed and human transfer is unclear, which aligns with the preclinical nature of the evidence and the profile’s limitations.

1

Study evidence

Quercetin decreased tumor load in an in vivo murine lung cancer model without affecting body weight (reported in the abstract).

“In an in vivo model, quercetin decreased the tumor load without affecting the body weight.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper’s mechanistic cell-cycle pathway finding includes regulation of the p53–p21 axis, with CDKN1A upregulation and CDK1 downregulation.

    The story conveys a functional effect on cell division but omits the specific p53–p21/CDKN1A/CDK1 mechanism described in the profile.

    From in vitro cell culture; in vivo murine tumor efficacy

  • The in vivo murine model reported no overt body-weight effect as a tolerability signal.

    The paper profile notes decreased tumor load without affecting body weight, but the story presentation does not report this tolerability/body-weight element.

    From in vivo murine tumor efficacy

  • Quercetin was reported to reprogram the splenic CD8+ T-cell transcriptome, including Ltf upregulation and downregulation of several genes linked by the authors to proliferation/metastasis programs.

    The story mentions general immune effects but does not include the splenic CD8+ T-cell transcriptomic findings or the named gene-expression changes.

    From Splenic CD8+ T‑cell transcriptome profiling (murine, implied in vivo exposure)

  • Quercetin was reported to condition the gut microbiome by increasing the abundance of SCFA-producing bacteria.

    The story presentation does not mention the microbiome or SCFA-producing bacteria, which is a secondary but distinct paper element.

    From In vivo (murine) gut microbiome compositional profiling (methodological details not specified in abstract)

6 things the story did carry across
  • In vitro experiments in human lung cancer cell lines A549 and H520 found quercetin-related cell-cycle arrest, reduced proliferation, and suppressed migration.
  • Quercetin reduced oxidative stress in treated tumor cells in vitro.
  • The abstract reports dose-responsive downregulation of EGFR and PD-L1 on A549 cells, and also reports decreased Ki67.
  • In vivo murine lung cancer experiments reported decreased tumor load after quercetin treatment.
  • An ex vivo model showed induction of interferon alpha-2 after quercetin treatment.
  • The evidence is preclinical and does not establish human clinical effectiveness or transferability.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroQuercetin has direct anti-tumor effects on lung cancer cells by inducing cell-cycle arrest (p53–p21 axis), reducing oxidative stress, downregulating oncogenic/surface markers (EGFR, PD-L1, Ki67), and inhibiting proliferation/migration in human lung cancer cell lines.in vitro cell cultureExpand

In plain English

Abstract-reported in vitro experiments in human lung cancer cell lines (A549, H520) indicate that quercetin treatment is associated with cell-cycle arrest via the p53–p21 axis (with reported CDKN1A upregulation and CDK1 downregulation), reduced oxidative stress, decreased proliferation and migration, and dose-responsive reductions in surface oncogenic markers (EGFR, PD-L1) and Ki67.

Key findings

  • Quercetin induced tumor cell-cycle arrest via the p53–p21 axis in human lung cancer cell lines (A549 and H520), with reported upregulation of CDKN1A and downregulation of CDK1.
  • Quercetin attenuated proliferation and suppressed migration of lung tumor cells in the tested cell lines (A549, H520).
“we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models”
What this piece can’t prove
  • Summary is based solely on abstract text; primary paper may contain additional experimental details not captured here.
  • Abstract does not provide quantitative effect sizes, treatment concentrations, exposure durations, replicate numbers, or statistical analyses for the in vitro endpoints.
  • Findings are limited to two established cancer cell lines in vitro and may not generalize to in vivo biology or clinical settings without further evidence.

1 further detail could not be confirmed from the summary.

2in vivo animalQuercetin reduces tumor burden in an in vivo murine lung cancer model without overt toxicity (e.g., no body-weight loss), with associated tumor biomarker changes consistent with cell-cycle control.in vivo murine tumor efficacyExpand

In plain English

The abstract reports that quercetin reduced tumor load in an in vivo murine lung cancer model without affecting body weight, and that quercetin treatment was associated with tumor-associated biomarker changes consistent with cell-cycle control (upregulation of CDKN1A and downregulation of CDK1) and decreased expression of proliferation/oncogenic markers (Ki67, EGFR, PD-L1). The report does not provide effect sizes, animal model details, dosing/regimen, sample sizes, or experimental design details in the abstract.

Key findings

  • Quercetin decreased tumor load in an in vivo murine lung cancer model without affecting body weight (reported in the abstract).
  • Quercetin treatment was associated with tumor/tissue biomarker changes consistent with cell-cycle control: upregulation of CDKN1A and downregulation of CDK1 (reported for 'murine models and human lung cancer cell lines'), and decreased expression of Ki67, EGFR, and PD-L1 (overview statement in abstract).
“In an in vivo model, quercetin decreased the tumor load without affecting the body weight.”
What this piece can’t prove
  • Some biomarker statements are presented across 'murine models and human cell lines' or are shown in vitro (A549), creating ambiguity about which measurements derive from the specific in vivo efficacy experiment.

4 further details could not be confirmed from the summary.

3ex vivo animalQuercetin modulates anti-tumor immune pathways ex vivo and systemically, including induction of IFN-α2 and reprogramming of splenic CD8+ T-cell transcriptome (e.g., upregulating Ltf and downregulating multiple oncogene programs).Ex vivo cytokine induction assayExpand

In plain English

The paper reports that, in an ex vivo model, treatment with quercetin induced interferon alpha-2 (IFN-α2). The authors present this induction as evidence of quercetin's immunoregulatory/anti-tumor activity in the context of lung cancer. The abstract does not specify the source of ex vivo tissue/cells, the assay used to quantify IFN-α2, or the magnitude of induction.

Key findings

  • In an ex vivo model, quercetin treatment resulted in induction of interferon alpha-2 (IFN-α2), described by the authors as an anti-tumor cytokine.
“In the ex vivo model, quercetin treatment resulted in the induction of interferon alpha-2 (IFN-α2), a well-known anti-tumor cytokine.”
What this piece can’t prove
  • Lack of detail in abstract about ex vivo specimen source, quercetin dose/concentration, exposure duration, and assay methods.
  • Unclear whether the ex vivo finding was replicated across samples or is representative of systemic immune modulation.

1 further detail could not be confirmed from the summary.

4in vivo animalQuercetin modulates anti-tumor immune pathways ex vivo and systemically, including induction of IFN-α2 and reprogramming of splenic CD8+ T-cell transcriptome (e.g., upregulating Ltf and downregulating multiple oncogene programs).Splenic CD8+ T‑cell transcriptome profiling (murine, implied in vivo exposure)Expand

In plain English

In a murine in vivo context, quercetin is reported to 'reprogram' the splenic CD8+ T‑cell transcriptome, with specific gene-level changes: upregulation of Ltf and downregulation of multiple genes described as oncogenes or proliferation/metastasis-associated (POU6F1, Celsr1, ST3GAL6, Sik2, Adnp, Jun). The claim is presented at the transcriptomic/omics level in the abstract without accompanying methodological detail in the abstract.

Key findings

  • Quercetin 'reprogrammed the splenic CD8+ T cell transcriptome' in mice, with upregulation of Ltf and downregulation of POU6F1, Celsr1, ST3GAL6, Sik2, Adnp, and Jun (as reported in the abstract).
“Quercetin also reprogrammed the splenic CD8 + T cell transcriptome, most notably by upregulating the tumor suppressor gene Ltf while also downregulating several oncogenes involved in proliferation and metastasis, namely POU6F1, Celsr1, ST3GAL6, Sik2, Adnp, and Jun.”
What this piece can’t prove
  • No details on cell-isolation methods (sorting markers, purity) or whether CD8+ cells were analyzed as bulk populations or single cells.

3 further details could not be confirmed from the summary.

5in vivo animalQuercetin conditions the gut microbiome (increasing SCFA-producing bacteria), potentially contributing to immunomodulatory/anti-tumor effects.In vivo (murine) gut microbiome compositional profiling (methodological details not specified in abstract)Expand

In plain English

In the reported in vivo experiments, quercetin 'conditioned the gut microbiome', with the authors stating it promoted an increased abundance of short-chain fatty acid (SCFA)-producing bacterial taxa.

Key findings

  • Quercetin treatment conditioned the gut microbiome, promoting an increased abundance of SCFA-producing bacteria.
“It also conditioned the gut microbiome, promoting an increased abundance of SCFA-producing bacteria.”
What this piece can’t prove
  • Unclear which bacterial taxa were classified as SCFA-producers and what criteria were used for that classification.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

CandidateOpen access

Chemical Annotation and Biological Evaluation of Prenylated Benzophenone-Rich Fractions from Clusia grandiflora Fruits: Integrated In Vitro and In Silico Analyses of Antileishmanial Activity, Nitric Oxide Modulation, and Stage-Dependent Cell Death Phenotypes.

2026 · Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)

And 32 more candidates considered.